Gut Bacteria and Immunotherapy for Triple-Negative Breast Cancer
Part of Cancer, Skin clinical trials.
This study looks at how bacteria in your gut might affect the way your body responds to immunotherapy for triple-negative breast cancer. It focuses on women who are overweight or obese and are about to start treatment with pembrolizumab before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been newly diagnosed with triple-negative breast cancer that hasn't been treated yet.
- You plan to start immunotherapy (pembrolizumab) before surgery.
- You have a BMI of 25 or higher (overweight or obesity).
- You do not have an active autoimmune disease, a digestive disorder like Crohn's or IBS, or need long-term antibiotics.
- You are not pregnant, breastfeeding, or planning to become pregnant in the next 24 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your diet and the natural bacteria in your gut (microbiome) may affect how well chemotherapy and immunotherapy work for early-stage triple-negative breast cancer. By participating, you may help doctors understand if certain gut bacteria can improve treatment outcomes.
This trial tests whether a treatment that targets your gut bacteria (microbiome) can help fight triple-negative breast cancer before surgery. It is for people with newly diagnosed, untreated triple-negative breast cancer that has not spread far.
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
This study tests a lifestyle program (diet, exercise, and support) for women with triple-negative breast cancer who are getting chemotherapy plus immunotherapy before surgery. The goal is to see if healthy habits can help during treatment.
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
This study looks at how gut bacteria may relate to how well immunotherapy works in people with advanced or returning gynecologic cancer. You may be asked to give stool samples several times so researchers can measure changes in your gut microbiome.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.